Charles Russell Speechlys has advised Kreos Capital V (UK) Limited on its additional growth capital investment of up to €20 million in Kiadis Pharma NV (“Kiadis Pharma”), a Dutch company listed on Euronext Amsterdam and Euronext Brussels. This is a follow on investment by Kreos subsequent to its €15 million growth capital investment in Kiadis Pharma which completed in 2017.

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders. Kiadis Pharma is focused on two therapeutic indications: leukemia (a common form of blood cancer) with its lead product ATIR101 and thalassemia (an inherited blood disorder) with its ATIR201 product.

Kiadis Pharma announced to the market that it will use the financing to advance the Phase 3 clinical development of ATIR101, to prepare for a possible commercial launch in Europe and for general corporate purposes.

The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Legal Director), Amelly Kok (Associate) and Alice Mason (Corporate Trainee) from our Corporate Team. Foreign counsels whom have advised on this transaction are Fruytier Lawyers in Business (Dutch law), Borden Ladner Gervais LLP (Canadian law), Avocado Rechtsanwälte (German law) and Golenbock Eiseman Assor Bell & Peskoe LLP (US law).